A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

K. Fizazi; M. Hussain; F. Saad; N. Shore; U. De Giorgi; E. Efstathiou; U. Ferreira; P. Ivashchenko; K. Madziarska; M. Al-Adhami; K. Modelska; D. Phung; J. Steinberg; C. N. Sternberg

doi:10.1093/annonc/mdy284.014

A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

K. Fizazi, M. Hussain, F. Saad, N. Shore, U. De Giorgi, E. Efstathiou, U. Ferreira, P. Ivashchenko, K. Madziarska, M. Al-Adhami, K. Modelska, D. Phung, J. Steinberg, C. N. Sternberg

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii277-viii278
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy284.014
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy284.014

Cite this

Fizazi, K., Hussain, M., Saad, F., Shore, N., De Giorgi, U., Efstathiou, E., Ferreira, U., Ivashchenko, P., Madziarska, K., Al-Adhami, M., Modelska, K., Phung, D., Steinberg, J., & Sternberg, C. N. (2018). A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii277-viii278. https://doi.org/10.1093/annonc/mdy284.014

Fizazi, K. ; Hussain, M. ; Saad, F. et al. / A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC) : Results of PROSPER by age and region. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii277-viii278.

@article{b17f4785f2da4b7b9c12836266f1b90e,

title = "A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region",

author = "K. Fizazi and M. Hussain and F. Saad and N. Shore and \{De Giorgi\}, U. and E. Efstathiou and U. Ferreira and P. Ivashchenko and K. Madziarska and M. Al-Adhami and K. Modelska and D. Phung and J. Steinberg and Sternberg, \{C. N.\}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy284.014",

language = "English (US)",

volume = "29",

pages = "viii277--viii278",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Fizazi, K, Hussain, M, Saad, F, Shore, N, De Giorgi, U, Efstathiou, E, Ferreira, U, Ivashchenko, P, Madziarska, K, Al-Adhami, M, Modelska, K, Phung, D, Steinberg, J & Sternberg, CN 2018, 'A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii277-viii278. https://doi.org/10.1093/annonc/mdy284.014

A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. / Fizazi, K.; Hussain, M.; Saad, F. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii277-viii278.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC)

T2 - Results of PROSPER by age and region

AU - Fizazi, K.

AU - Hussain, M.

AU - Saad, F.

AU - Shore, N.

AU - De Giorgi, U.

AU - Efstathiou, E.

AU - Ferreira, U.

AU - Ivashchenko, P.

AU - Madziarska, K.

AU - Al-Adhami, M.

AU - Modelska, K.

AU - Phung, D.

AU - Steinberg, J.

AU - Sternberg, C. N.

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://www.scopus.com/pages/publications/85061110140

UR - http://www.scopus.com/inward/citedby.url?scp=85061110140&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy284.014

DO - 10.1093/annonc/mdy284.014

M3 - Article

C2 - 32136636

SN - 0923-7534

VL - 29

SP - viii277-viii278

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Fizazi K, Hussain M, Saad F, Shore N, De Giorgi U, Efstathiou E et al. A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii277-viii278. doi: 10.1093/annonc/mdy284.014

A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this